338 related articles for article (PubMed ID: 12755095)
1. IRBs and monitoring the safety of clinical trials.
Maloney DM
Hum Res Rep; 2003 Jan; 18(1):3. PubMed ID: 12755095
[No Abstract] [Full Text] [Related]
2. IRBs, data sharing, and privacy of human subjects.
Maloney DM
Hum Res Rep; 2002 Apr; 17(4):3. PubMed ID: 12374179
[No Abstract] [Full Text] [Related]
3. Safety boards must report their conclusions to IRBs.
Maloney DM
Hum Res Rep; 1999 Oct; 14(10):3. PubMed ID: 11658061
[No Abstract] [Full Text] [Related]
4. The IRB is not a data and safety monitoring board.
Bankert E; Amdur R
IRB; 2000; 22(6):9-11. PubMed ID: 11883486
[No Abstract] [Full Text] [Related]
5. Continued concern: human subject protection, the institutional review board, and continuing review.
Hoffman S
Tenn Law Rev; 2001; 68(4):725-70. PubMed ID: 16189912
[No Abstract] [Full Text] [Related]
6. Institutional review boards (IRBs) and working with adverse event reports.
Maloney DM
Hum Res Rep; 2005 Dec; 20(12):1-3. PubMed ID: 16607708
[No Abstract] [Full Text] [Related]
7. How institutional review boards (IRBs) can handle adverse event reports.
Maloney DM
Hum Res Rep; 2006 Jan; 21(1):1-3. PubMed ID: 16789305
[No Abstract] [Full Text] [Related]
8. Regulating clinical research: informed consent, privacy, and IRBs.
Hoffman S
Cap Univ Law Rev; 2003; 31(1):71-91. PubMed ID: 15295833
[No Abstract] [Full Text] [Related]
9. Safety panel backs principle of gene-therapy trials.
Check E
Nature; 2002 Dec; 420(6916):595. PubMed ID: 12478252
[No Abstract] [Full Text] [Related]
10. Improving protection for research subjects.
Steinbrook R
N Engl J Med; 2002 May; 346(18):1425-30. PubMed ID: 11986426
[No Abstract] [Full Text] [Related]
11. Institutional review boards must conduct safety review.
Maloney DM
Hum Res Rep; 2005 Feb; 20(2):3. PubMed ID: 15839005
[No Abstract] [Full Text] [Related]
12. Reporting problems in human research and resultant investigations by IRBs.
Maloney DM
Hum Res Rep; 2002 Aug; 17(8):6-7. PubMed ID: 12731495
[No Abstract] [Full Text] [Related]
13. IRBs and financial conflict of interest.
Maloney DM
Hum Res Rep; 2000 Nov; 15(11):3. PubMed ID: 11767804
[No Abstract] [Full Text] [Related]
14. A central institutional review board for multi-institutional trials.
Christian MC; Goldberg JL; Killen J; Abrams JS; McCabe MS; Mauer JK; Wittes RE
N Engl J Med; 2002 May; 346(18):1405-8. PubMed ID: 11986418
[No Abstract] [Full Text] [Related]
15. Current issues in clinical research and the development of new pharmaceuticals.
Goldhammer A
Account Res; 2001; 8(4):283-91. PubMed ID: 12481798
[TBL] [Abstract][Full Text] [Related]
16. Research involving children: regulations, review boards and reform.
Gandhi R
J Health Care Law Policy; 2005; 8(2):264-330. PubMed ID: 16471026
[No Abstract] [Full Text] [Related]
17. IRB reform.
Slater EE
N Engl J Med; 2002 May; 346(18):1402-4. PubMed ID: 11986417
[No Abstract] [Full Text] [Related]
18. Restoring public trust in gene therapy.
Kennedy EM
J Biolaw Bus; 2001; 4(3):3-4. PubMed ID: 12962103
[No Abstract] [Full Text] [Related]
19. Central IRBs: why are some institutions reluctant to sign on?
McNeil C
J Natl Cancer Inst; 2005 Jul; 97(13):953-5. PubMed ID: 15998943
[No Abstract] [Full Text] [Related]
20. Numerous violations of federal informed consent requirements.
Maloney DM
Hum Res Rep; 2004 Jan; 19(1):1-3. PubMed ID: 14997901
[No Abstract] [Full Text] [Related]
[Next] [New Search]
